Solvonis Therapeutics CEO on name change, Awakn acquisition and 2025 priorities [Video]

Solvonis Therapeutics CEO Anthony Tennyson talked with Proactive’s Stephen Gunnion about the company’s rebranding from Graft Polymer (UK) PLC (LSE:GPL) to Solvonis Therapeutics PLC, reflecting its commitment to advancing mental health and substance use disorder treatments. Tennyson highlighted Solvonis’ plans to acquire Awakn Life Sciences in an all-stock deal, emphasising Awakn’s promising data, experienced team, and valuation.

Awakn’s lead program targeting severe alcohol use disorder has entered Phase 3 trials with UK government funding, an achievement Tennyson described as “unheard of for a Phase 3 trial in this indication.” The program showed a 50% reduction in heavy drinking days and a remarkable 86% abstinence rate over six months post-treatment.

or 2025, Solvonis aims to complete the acquisition efficiently, progress Awakn’s lead program, and advance a secondary program targeting alcohol use disorder in the US. Tennyson stated, “We’re very happy with what 2025 will hold for the company and our shareholders.”

…